-

NanoTemper Enters Protein Production Market With Andromeda, Helping Biopharma and CROs to Increase Efficiency of Expression Screening for Membrane Proteins

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, enters the protein production market with the release of Andromeda, an instrument that determines optimal expression levels and thermal stability of recombinant membrane proteins in crude lysates — something unachievable using currently available methods or technologies on their own. As a result, Andromeda increases the efficiency of protein production teams at CROs and Biopharma, who now arrive at purification much faster and with the most stable proteins because they have insights on thermal stability during expression screening.

“Protein production teams promise to deliver high-quality recombinant proteins, and when affinity screening campaigns or crystallization protocols fail, the blame usually falls on them. Andromeda helps them deliver on that promise more quickly and efficiently,” says Stefan Duhr, co-CEO of NanoTemper.

“To select for the best expression conditions, protein production teams currently focus mostly on expression levels, while protein stability characterization is carried out separately or after purification. This involves a combination of methods like SDS-PAGE, FSEC, and FSEC-TS, which can be tedious and have a low throughput.” shared Jocelyn Davé, Chief Product Officer at NanoTemper. “Andromeda, on the other hand, reveals expression levels and stability characterization from a single assay in crude lysates before teams commit to purification.”

With Andromeda, protein production teams can now hand over high-quality proteins faster and save themselves the trouble of rescreening by knowing the stability of proteins early on. Andromeda provides all the valuable information needed to help them quickly and efficiently select for conditions that result in high expression levels of quality proteins.

Visit nanotempertech.com/andromeda to find out more details. For the most up-to-date information, follow NanoTemper on LinkedIn, Facebook, and Twitter.

About NanoTemper Technologies

Our mission at NanoTemper Technologies is to enable everyone to do science that matters by always pushing the limits. We’re focused on making tools that address challenging characterizations for use in drug discovery and basic science research. Working with scientists striving to make a difference in the world gets us excited. If you’re facing challenges with affinity screening, molecular interactions, protein stability, protein expression, or protein quality, let’s talk.

Contacts

John Valdez
john.valdez@nanotempertech.com
+1-415-670-0424

NanoTemper Technologies



Contacts

John Valdez
john.valdez@nanotempertech.com
+1-415-670-0424

More News From NanoTemper Technologies

NanoTemper Brings Spectral Shift Technology to the Protein Production Market With Andromeda X, Enabling Biopharma and CROs to Increase Efficiency of Expression Screening for Recombinant Protein Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who...

NanoTemper Technologies Launches Human Fc Labeling Kit, Accelerating Biologics Affinity Screening Workflows

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, creator of high-quality, easy-to-learn biophysical tools for drug discovery, launches a new way for biologics researchers to screen humanized antibody therapeutics with the release of their Human Fc Labeling Kit. Optimized for use with Spectral Shift technology, an in-solution affinity screening method, scientists looking for innovative ways to accelerate candidate selection will appreciate the ability to measure affinities...

NanoTemper Technologies Unveils Biotinylated Target Labeling Kit, Empowering Scientists in Pharma Industry to Tackle Challenging Drug Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the...
Back to Newsroom